vir biotechnology news

Vir, Morgan Stanley and Prostate Cancer

Morgan Stanley upgrades Vir Biotechnology to 'overweight,' raises PT to $20

Morgan Stanley (NYSE:MS) analysts have upgraded Vir Biotechnology (NASDAQ:VIR) to an "overweight" rating, shifting from "equal-weight," and have also increased their price target to $20 from $10. The analysts flagged

Seeking Alpha on MSN · 11h

Vir Biotech upgraded at Morgan Stanley on cancer drug data

Vir Biotechnology (VIR) stock was upgraded by Morgan Stanley after the company posted trial data for two antitumor agents developed with Sanofi (SNY). Read more here.

Benzinga.com · 1d

Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why

Vir Biotechnology's Phase 1 trials reveal promising safety and efficacy for dual-masked T-cell engagers targeting HER2 and PSMA in cancer therapies.

Business Insider · 17h

Vir Biotechnology upgraded to Overweight from Equal Weight at Morgan Stanley

Morgan Stanley analyst Michael Ulz upgraded Vir Biotechnology (VIR) to Overweight from Equal Weight with a price target of $20, up from $10.

Fintel on MSN · 1d

Morgan Stanley Upgrades NetEase (NETTF)

Fintel reports that on January 8, 2025, Morgan Stanley upgraded their outlook for NetEase (OTCPK:NETTF) from Equal-Weight to Overweight. Analyst Price Forecast Suggests 20.17% Upside As of December 23,

14h

Vir Biotechnology: A Rocket Off Phase 1 Data... What Could Go Wrong?

Vir Biotechnology's recent share price rally is driven by their promising cancer program. Having shot to over a $1.5B market ...

Zacks.com on MSN11h

VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates

Vir Biotechnology, Inc. VIR announced encouraging initial data from a phase I study that evaluated its investigational ...

10h

Vir Biotechnology Reports Positive Phase 2 Results, Shares Surge by 58%

Following the publication of encouraging results from Phase 2 studies for two investigational cancer treatments, Vir ...

19h

Vir Biotechnology (VIR) Gets a Buy from Barclays

In a report released today, Gena Wang from Barclays assigned a Buy rating to Vir Biotechnology (VIR – Research Report), with a price target of ...

bovnews15h

Vir Biotechnology Inc (VIR) Stock: Surpassing Expectations in the Market?

JP Morgan has recently reduced Vir Biotechnology Inc (VIR) stock to Neutral rating, as announced on January 29, 2024, according to Finviz. Earlier, on September 8, 2023, BofA Securities had reduced ...

14h

Vir Biotechnology Reports Promising Trial Results for Cancer Therapies

Vir Biotechnology ( (VIR) ) has issued an update. Vir Biotechnology announced promising Phase 1 trial results for its ...

Vir Biotechnology, Once a Hot Covid Stock, Finds New Path Forward in Cancer

Shares of the battered biotech Vir Biotechnology were up more than 70% on Wednesday, as the company reported its first positive data since it executed a major pivot last summer. A hot stock during the ...

bovnews1d

Vir Biotechnology (VIR) Makes Big Waves: Why Today’s Stock Surge Matters

Vir Biotechnology, Inc. (Nasdaq: VIR) is experiencing a massive surge in the stock market, climbing an impressive +74.08% or $5.85 to $13.74 in Wednesday’s trading session at 12:22 PM EST. This sharp ...

Vir Biotechnology’s Early Stage Developments and Valuation Lead to Hold Rating Amid Long-Term Promise and Near-Term Uncertainties

Eric Joseph, an analyst from J.P. Morgan, maintained the Hold rating on Vir Biotechnology (VIR – Research Report). The associated price target ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Vir, Morgan Stanley and Prostate Cancer

Related topics